174 related articles for article (PubMed ID: 24007469)
1. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.
VanderVeen N; Paran C; Krasinkiewicz J; Zhao L; Palmer D; Hervey-Jumper S; Ng P; Lowenstein PR; Castro MG
Hum Gene Ther Clin Dev; 2013 Sep; 24(3):116-26. PubMed ID: 24007469
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
VanderVeen N; Raja N; Yi E; Appelman H; Ng P; Palmer D; Zamler D; Dzaman M; Lowenstein PR; Castro MG
Hum Gene Ther Methods; 2016 Jun; 27(3):98-111. PubMed ID: 27056322
[TBL] [Abstract][Full Text] [Related]
3. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.
Puntel M; Muhammad AK; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Bondale NS; Lerner J; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
J Virol; 2010 Jun; 84(12):6007-17. PubMed ID: 20375153
[TBL] [Abstract][Full Text] [Related]
4. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.
Puntel M; A K M GM; Farrokhi C; Vanderveen N; Paran C; Appelhans A; Kroeger KM; Salem A; Lacayo L; Pechnick RN; Kelson KR; Kaur S; Kennedy S; Palmer D; Ng P; Liu C; Krasinkiewicz J; Lowenstein PR; Castro MG
Toxicol Appl Pharmacol; 2013 May; 268(3):318-30. PubMed ID: 23403069
[TBL] [Abstract][Full Text] [Related]
5. Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.
VanderVeen N; Paran C; Appelhans A; Krasinkiewicz J; Lemons R; Appelman H; Doherty R; Palmer D; Ng P; Lowenstein PR; Castro MG
Mol Ther Methods Clin Dev; 2014 Feb; 1():10-. PubMed ID: 25068145
[TBL] [Abstract][Full Text] [Related]
6. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.
Muhammad AK; Puntel M; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Lawrence K; Bondale NS; Lerner J; Baker GJ; Foulad D; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
Clin Pharmacol Ther; 2010 Aug; 88(2):204-13. PubMed ID: 20164833
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial.
Muhammad AK; Xiong W; Puntel M; Farrokhi C; Kroeger KM; Salem A; Lacayo L; Pechnick RN; Kelson KR; Palmer D; Ng P; Liu C; Lowenstein PR; Castro MG
Hum Gene Ther Methods; 2012 Aug; 23(4):271-84. PubMed ID: 22950971
[TBL] [Abstract][Full Text] [Related]
8. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.
Candolfi M; Pluhar GE; Kroeger K; Puntel M; Curtin J; Barcia C; Muhammad AK; Xiong W; Liu C; Mondkar S; Kuoy W; Kang T; McNeil EA; Freese AB; Ohlfest JR; Moore P; Palmer D; Ng P; Young JD; Lowenstein PR; Castro MG
Neuro Oncol; 2007 Jul; 9(3):245-58. PubMed ID: 17522335
[TBL] [Abstract][Full Text] [Related]
9. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
Candolfi M; Yagiz K; Foulad D; Alzadeh GE; Tesarfreund M; Muhammad AK; Puntel M; Kroeger KM; Liu C; Lee S; Curtin JF; King GD; Lerner J; Sato K; Mineharu Y; Xiong W; Lowenstein PR; Castro MG
Clin Cancer Res; 2009 Jul; 15(13):4401-14. PubMed ID: 19570774
[TBL] [Abstract][Full Text] [Related]
10. Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.
Umemura Y; Orringer D; Junck L; Varela ML; West MEJ; Faisal SM; Comba A; Heth J; Sagher O; Leung D; Mammoser A; Hervey-Jumper S; Zamler D; Yadav VN; Dunn P; Al-Holou W; Hollon T; Kim MM; Wahl DR; Camelo-Piragua S; Lieberman AP; Venneti S; McKeever P; Lawrence T; Kurokawa R; Sagher K; Altshuler D; Zhao L; Muraszko K; Castro MG; Lowenstein PR
Lancet Oncol; 2023 Sep; 24(9):1042-1052. PubMed ID: 37657463
[TBL] [Abstract][Full Text] [Related]
11. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AK; Pechnick RN; Lowenstein PR; Castro MG
Mol Ther; 2008 Apr; 16(4):682-90. PubMed ID: 18283279
[TBL] [Abstract][Full Text] [Related]
12. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
[TBL] [Abstract][Full Text] [Related]
13. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
King GD; Muhammad AK; Larocque D; Kelson KR; Xiong W; Liu C; Sanderson NS; Kroeger KM; Castro MG; Lowenstein PR
Mol Ther; 2011 Oct; 19(10):1793-801. PubMed ID: 21505426
[TBL] [Abstract][Full Text] [Related]
14. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
King GD; Muhammad AK; Curtin JF; Barcia C; Puntel M; Liu C; Honig SB; Candolfi M; Mondkar S; Lowenstein PR; Castro MG
Neuro Oncol; 2008 Feb; 10(1):19-31. PubMed ID: 18079358
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral-mediated gene transfer into the canine brain in vivo.
Candolfi M; Kroeger KM; Pluhar GE; Bergeron J; Puntel M; Curtin JF; McNiel EA; Freese AB; Ohlfest JR; Moore P; Lowenstein PR; Castro MG
Neurosurgery; 2007 Jan; 60(1):167-77; discussion 178. PubMed ID: 17228266
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral vector-mediated gene therapy for gliomas: coming of age.
Castro MG; Candolfi M; Wilson TJ; Calinescu A; Paran C; Kamran N; Koschmann C; Moreno-Ayala MA; Assi H; Lowenstein PR
Expert Opin Biol Ther; 2014 Sep; 14(9):1241-57. PubMed ID: 24773178
[TBL] [Abstract][Full Text] [Related]
17. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
[TBL] [Abstract][Full Text] [Related]
18. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
Candolfi M; King GD; Yagiz K; Curtin JF; Mineharu Y; Muhammad AK; Foulad D; Kroeger KM; Barnett N; Josien R; Lowenstein PR; Castro MG
Neoplasia; 2012 Aug; 14(8):757-70. PubMed ID: 22952428
[TBL] [Abstract][Full Text] [Related]
19. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
[TBL] [Abstract][Full Text] [Related]
20. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
Ali S; King GD; Curtin JF; Candolfi M; Xiong W; Liu C; Puntel M; Cheng Q; Prieto J; Ribas A; Kupiec-Weglinski J; van Rooijen N; Lassmann H; Lowenstein PR; Castro MG
Cancer Res; 2005 Aug; 65(16):7194-204. PubMed ID: 16103070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
